{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:58:40Z","timestamp":1793336320214,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s10620-023-08260-1","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T19:03:03Z","timestamp":1707764583000},"page":"1421-1429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Primary Sclerosing Cholangitis Limited to Intrahepatic Bile Ducts Has Distinctly Better Prognosis"],"prefix":"10.1007","volume":"69","author":[{"given":"Vijay S.","family":"Are","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Gromski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Akisik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Vilar-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Lammert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Ghabril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-1577","authenticated-orcid":false,"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"8260_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D et al. Primary sclerosing cholangitis\u2014a comprehensive review. J Hepatol 2017;67:1298\u20131323.","journal-title":"J Hepatol"},{"key":"8260_CR2","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","volume":"68","author":"MH Chapman","year":"2019","unstructured":"Chapman MH, Thorburn D, Hirschfield GM et al. British Society of Gastroenterology and UK-PSC guidelines for diagnosing and managing primary sclerosing cholangitis. Gut 2019;68:1356\u20131378.","journal-title":"Gut"},{"key":"8260_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/hep.23294","volume":"51","author":"R Chapman","year":"2010","unstructured":"Chapman R, Fevery J, Kalloo A et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660\u2013678.","journal-title":"Hepatology"},{"key":"8260_CR4","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","volume":"382","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield GM, Karlsen TH, Lindor KD et al. Primary sclerosing cholangitis. Lancet 2013;382:1587\u20131599.","journal-title":"Lancet"},{"key":"8260_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ajg.2015.112","volume":"110","author":"KD Lindor","year":"2015","unstructured":"Lindor KD, Kowdley KV, Harrison ME et al. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015;110:646\u2013659.","journal-title":"Am J Gastroenterol"},{"key":"8260_CR6","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1016\/S0618-8278(19)30812-6","volume":"70","author":"M Walmsley","year":"2019","unstructured":"Walmsley M, Leburgue A, Thorburn D et al. FRI-062-Identifying research priorities in primary sclerosing cholangitis: driving clinically meaningful change from the patients\u2019 perspective. J Hepatol 2019;70:e412\u2013e413.","journal-title":"J Hepatol"},{"key":"8260_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/gut.51.5.731","volume":"51","author":"E Bj\u00f6rnsson","year":"2002","unstructured":"Bj\u00f6rnsson E, Boberg KM, Cullen S et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002;51:731\u2013735.","journal-title":"Gut"},{"key":"8260_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0168-8278(02)00036-3","volume":"36","author":"U Broom\u00e9","year":"2002","unstructured":"Broom\u00e9 U, Glaumann H, Lindst\u00f6m E et al. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002;36:586\u2013589.","journal-title":"J Hepatol"},{"key":"8260_CR9","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1053\/jhep.2002.33202","volume":"35","author":"P Angulo","year":"2002","unstructured":"Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002;35:1494\u20131500.","journal-title":"Hepatology"},{"key":"8260_CR10","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","volume":"152","author":"TJ Weismuller","year":"2017","unstructured":"Weismuller TJ, Trivedi PJ, Bergquist A et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology 2017;152:1975-1984.e8.","journal-title":"Gastroenterology"},{"key":"8260_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.7326\/0003-4819-102-5-581","volume":"102","author":"A Wee","year":"1985","unstructured":"Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985;102:581\u2013587.","journal-title":"Ann Intern Med"},{"key":"8260_CR12","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/hep.30479","volume":"69","author":"EC Goode","year":"2019","unstructured":"Goode EC, Clark AB, Mells GF et al. Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system. Hepatology 2019;69:2120\u20132135.","journal-title":"Hepatology"},{"key":"8260_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/apt.13516","volume":"43","author":"J Fevery","year":"2016","unstructured":"Fevery J, Van Steenbergen W, Van Pelt J et al. Patients with large-duct primary sclerosing cholangitis and Crohn\u2019s disease have a better outcome than those with ulcerative colitis, or without IBD. Aliment Pharmacol Ther 2016;43:612\u2013620.","journal-title":"Aliment Pharmacol Ther"},{"key":"8260_CR14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.cgh.2017.10.028","volume":"16","author":"DS Goldberg","year":"2018","unstructured":"Goldberg DS, Levy C, Yimam K et al. Primary sclerosing cholangitis is not rare among blacks in a multicenter North American Consortium. Clin Gastroenterol Hepatol 2018;16:591\u2013593.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8260_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0168-8278(01)00251-3","volume":"36","author":"A Stiehl","year":"2002","unstructured":"Stiehl A, Rudolph G, Kl\u00f6ters-Plachky P et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002;36:151\u2013156.","journal-title":"J Hepatol"},{"key":"8260_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/j.1572-0241.2004.04106.x","volume":"99","author":"E Bj\u00f6rnsson","year":"2004","unstructured":"Bj\u00f6rnsson E, Lindqvist-Ottosson J, Asztely M et al. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004;99:502\u2013508.","journal-title":"Am J Gastroenterol"},{"key":"8260_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","volume":"14","author":"S Mittal","year":"2016","unstructured":"Mittal S, El-Serag HB, Sada YH et al. Hepatocellular carcinoma in the absence of cirrhosis in united states veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14:124\u201331.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8260_CR18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","volume":"75","author":"WR Kim","year":"2000","unstructured":"Kim WR, Therneau TM, Wiesner RH et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688\u2013694.","journal-title":"Mayo Clin Proc"},{"key":"8260_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/hep.23277","volume":"51","author":"SY Bangarulingam","year":"2010","unstructured":"Bangarulingam SY, Bjornsson E, Enders F et al. Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology 2010;51:174\u2013180.","journal-title":"Hepatology"},{"key":"8260_CR20","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kulik LM, Sirlin CB et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723\u2013750.","journal-title":"Hepatology"},{"key":"8260_CR21","unstructured":"www.cdc.gov\/nchs\/ndi\/index.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fndi.htm. (accessed on January 1, 2023)."},{"key":"8260_CR22","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.bbadis.2017.08.020","volume":"1864","author":"BK Chung","year":"2018","unstructured":"Chung BK, Karlsen TH, Folseraas T. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. Biochim Biophys Acta 2018;1864:1390\u20131400.","journal-title":"Biochim Biophys Acta"},{"key":"8260_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1053\/j.gastro.2009.03.035","volume":"137","author":"FP Lemaigre","year":"2009","unstructured":"Lemaigre FP. Mechanisms of liver development: concepts for understanding liver disorders and design of novel therapies. Gastroenterology 2009;137:62\u201379.","journal-title":"Gastroenterology"},{"key":"8260_CR24","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/dvdy.21530","volume":"237","author":"AI Masyuk","year":"2008","unstructured":"Masyuk AI, Masyuk TV, LaRusso NF. Cholangiocyte primary cilia in liver health and disease. Dev Dyn 2008;237:2007\u20132012.","journal-title":"Dev Dyn"},{"key":"8260_CR25","first-page":"767","volume":"274","author":"G Alpini","year":"1998","unstructured":"Alpini G, Glaser SS, Ueno Y et al. Heterogeneity of the proliferative capacity of rat cholangiocytes after bile duct ligation. Am J Physiol 1998;274:767\u2013775.","journal-title":"Am J Physiol"},{"key":"8260_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hep.510290242","volume":"29","author":"GD LeSage","year":"1999","unstructured":"LeSage GD, Benedetti A, Glaser S et al. Acute carbon tetrachloride feeding selectively damages large, but not small, cholangiocytes from normal rat liver. Hepatology 1999;29:307\u2013319.","journal-title":"Hepatology"},{"key":"8260_CR27","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/hep.27085","volume":"60","author":"R Liu","year":"2014","unstructured":"Liu R, Zhao R, Zhou X et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology 2014;60:908\u2013918.","journal-title":"Hepatology"},{"key":"8260_CR28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/1541-7786.MCR-13-0503","volume":"12","author":"E Lozano","year":"2014","unstructured":"Lozano E, Sanchez-Vicente L, Monte MJ et al. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol Cancer Res 2014;12:91\u2013100.","journal-title":"Mol Cancer Res"},{"key":"8260_CR29","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291\u20133310.","journal-title":"Oncogene"},{"key":"8260_CR30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jhep.2004.07.016","volume":"41","author":"JH Yoon","year":"2004","unstructured":"Yoon JH, Gwak GY, Lee HS et al. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004;41:808\u2013814.","journal-title":"J Hepatol"},{"key":"8260_CR31","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/gast.2002.32410","volume":"122","author":"JH Yoon","year":"2002","unstructured":"Yoon JH, Higuchi H, Werneburg NW et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002;122:985\u2013993.","journal-title":"Gastroenterology"},{"key":"8260_CR32","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1377\/hlthaff.24.5.1214","volume":"24","author":"CJ McDonald","year":"2005","unstructured":"McDonald CJ, Overhage JM, Barnes M et al. The Indiana network for patient care: a working local health information infrastructure. An example of a working infrastructure collaboration that links data from five health systems and hundreds of millions of entries. Health Aff (Millwood) 2005;24:1214\u201320.","journal-title":"Health Aff (Millwood)"},{"key":"8260_CR33","doi-asserted-by":"publisher","first-page":"100595","DOI":"10.1016\/j.jhepr.2022.100595","volume":"4","author":"A Grigoriadis","year":"2022","unstructured":"Grigoriadis A, Imeen Ringe K, Bengtsson J et al. Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis. JHEP Rep 2022;4:100595.","journal-title":"JHEP Rep"},{"key":"8260_CR34","doi-asserted-by":"publisher","first-page":"100577","DOI":"10.1016\/j.jhepr.2022.100577","volume":"4","author":"N Cazzagon","year":"2022","unstructured":"Cazzagon N, El Mouhadi S, Vanderbecq Q et al. Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis. JHEP Rep 2022;4:100577.","journal-title":"JHEP Rep"},{"issue":"3","key":"8260_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.dld.2022.10.015","volume":"55","author":"L Cristoferi","year":"2023","unstructured":"Cristoferi L, Porta M, Bernasconi DP et al. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis. Dig Liver Dis. 2023;55(3):373\u2013380.","journal-title":"Dig Liver Dis."},{"key":"8260_CR36","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.cgh.2019.10.041","volume":"18","author":"JE Eaton","year":"2020","unstructured":"Eaton JE, Sen A, Hoodeshenas S et al. Changes in liver stiffness, measured by magnetic resonance elastography, associated with hepatic decompensation in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2020;18:1576\u20131583.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"8260_CR37","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1053\/j.gastro.2013.12.030","volume":"146","author":"C Corpechot","year":"2014","unstructured":"Corpechot C, Gaouar F, El Naggar A et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014;146:970\u20139 (quiz e15-6).","journal-title":"Gastroenterology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08260-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-08260-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08260-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T12:19:22Z","timestamp":1713442762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-08260-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["8260"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-08260-1","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are none for this paper. <b>For full disclosure:<\/b> Dr. Chalasani has ongoing paid consulting activities (or has had in the preceding 12\u00a0months) with Lilly, Madrigal Pharmaceuticals, Foresite Labs, Altimmune, Inc., Zydus Pharmaceuticals, Galectin Therapeutics, and Boehringer-Ingelheim. Dr. Chalasani receives research grant support from Exact Sciences and DSM, where his institution receives funding. Dr. Chalasani also has equity ownership in RestUp, Inc. Dr. Ghabril receives research grant support from Allergan. Dr. Vuppalanchi receives research grant support from Zydus Therapeutics Inc, Galectin Therapeutics, Gilead Sciences, Pliant Therapeutics, Novo Nordisk, Eli Lilly and Company and discloses honorarium for participating in data safety monitoring boards for Labcorp, Medpace, Enyo Pharma, Worldwide clinical trials, and Echosens. Drs. Are, Vilar-Gomez, Lammert, Akisik, and Gromski have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}